- Home
- XOMAO vs FOLD Comparison
XOMAO vs FOLD Comparison
Compare XOMAO & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAO
- FOLD
- Stock Information
- Founded
- XOMAO N/A
- FOLD 2002
- Country
- XOMAO United States
- FOLD United States
- Employees
- XOMAO 13
- FOLD N/A
- Industry
- XOMAO Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- XOMAO Health Care
- FOLD Health Care
- Exchange
- XOMAO Nasdaq
- FOLD Nasdaq
- Market Cap
- XOMAO N/A
- FOLD N/A
- IPO Year
- XOMAO N/A
- FOLD 2007
- Fundamental
- Price
- XOMAO $25.60
- FOLD $9.73
- Analyst Decision
- XOMAO
- FOLD Strong Buy
- Analyst Count
- XOMAO 0
- FOLD 8
- Target Price
- XOMAO N/A
- FOLD $16.71
- AVG Volume (30 Days)
- XOMAO N/A
- FOLD 2.5M
- Earning Date
- XOMAO N/A
- FOLD 11-06-2024
- Dividend Yield
- XOMAO N/A
- FOLD N/A
- EPS Growth
- XOMAO N/A
- FOLD N/A
- EPS
- XOMAO N/A
- FOLD N/A
- Revenue
- XOMAO N/A
- FOLD $493,671,000.00
- Revenue This Year
- XOMAO N/A
- FOLD $34.30
- Revenue Next Year
- XOMAO N/A
- FOLD $21.78
- P/E Ratio
- XOMAO N/A
- FOLD N/A
- Revenue Growth
- XOMAO N/A
- FOLD 32.58
- 52 Week Low
- XOMAO N/A
- FOLD $9.02
- 52 Week High
- XOMAO N/A
- FOLD $14.57
- Technical
- Relative Strength Index (RSI)
- XOMAO 59.77
- FOLD 44.43
- Support Level
- XOMAO $25.31
- FOLD $9.28
- Resistance Level
- XOMAO $25.49
- FOLD $9.99
- Average True Range (ATR)
- XOMAO 0.10
- FOLD 0.30
- MACD
- XOMAO 0.03
- FOLD 0.04
- Stochastic Oscillator
- XOMAO 81.81
- FOLD 47.22
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.